8 August 2017
Prostate cancer is the most common type of cancer and third leading cause of cancer death among men in the developed world. A team of scientists led by Prof. Jack Cuzick, Director, Wolfson Institute of Preventive Medicine has reviewed the most up-to-date evidence regarding prostate cancer risk factors, early detection of prostate cancer, therapeutic prevention of prostate cancer, and methods for distinguishing aggressive prostate cancers from indolent ones. International experts from the UK, Europe, USA and Australasia formed the review panel, which also included Dr. Mangesh Thorat from the Centre for Cancer Prevention at the Wolfson Institute of Preventive Medicine. The diversity of the review panel is a unique feature of this work, it included clinicians, epidemiologists and investigators of major prostate cancer prevention/screening trials and epidemiological studies.
This review highlights the important approaches for early detection and prevention of prostate cancer. Specifically, it outlines the current status of prostate cancer risk prediction, strategies to improve early detection and screening, assesses effectiveness of therapeutic prevention, identifies the most robust prognostication tools in management of screen detected prostate cancer. One area of lively discussion was the current and potential value of PSA based screening for which there were a range of opinions. The paper also identifies the specific research questions that need to be addressed in each of these areas to move the field forward.